Skip to main content
KoBioLabs, Inc. logo

KoBioLabs, Inc. — Investor Relations & Filings

Ticker · 348150 ISIN · KR7348150004 KO Manufacturing
Open in API
Filings indexed 174 across all filing types
Latest filing 2025-03-31 Board/Management Inform…
Country KR South Korea
Listing KO 348150

About KoBioLabs, Inc.

http://kobiolabs.com/en/

KoBioLabs, Inc. is a biotechnology company that develops innovative microbiome-based therapeutics. The company utilizes its proprietary Smartiome® platform, an integrated system for discovering novel drug candidates that employs AI-driven multi-omics analysis and a comprehensive microbiome library with a reverse-translation approach. KoBioLabs is focused on creating a pipeline of new drugs to treat a range of immune, metabolic, and brain disorders. The company also applies advanced technologies, including a microbe-based drug delivery system (mDDS) and biofoundry techniques, to enhance the efficacy of its treatments and address unmet medical needs.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details the appointment of specific individuals to the board of directors, including their names, terms, and professional backgrounds. This falls under the category of Board/Management Information (MANG), which covers announcements regarding changes in the company's board of directors.
2025-03-31 Korean
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details changes to the company's board of directors, specifically regarding outside directors. This falls under the category of Board/Management Information (MANG).
2025-03-31 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'GoBioLab' (주식회사 고바이오랩) for the fiscal year ending December 31, 2024. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. This is a comprehensive financial audit document, not an earnings release or a summary report. FY 2024
2025-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted by the company '고바이오랩'. It provides a summary of the audit opinion (unqualified/proper), key financial data (assets, liabilities, equity, revenue, profit/loss), and details regarding the auditor. While it contains financial data, it is a standardized regulatory disclosure form used in the Korean market to announce the receipt and submission of the audit report to the exchange, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing. FY 2024
2025-03-20 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for KoBioLabs. It details the date, location, agenda items (such as approval of financial statements, appointment of directors, and remuneration limits), and information regarding electronic voting and proxy procedures. This document is a standard proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and request their participation/votes. It fits the definition of a Proxy Solicitation & Information Statement (PSI).
2025-03-14 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by the company '고바이오랩'. It details the date, location, and agenda items for the upcoming Annual General Meeting (AGM), including the approval of financial statements, election of directors, and remuneration limits. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and the matters to be voted upon.
2025-03-06 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.